... — Cancer Research Institute Nivolumab Versus Everolimus in Advanced Renal-Cell Carcinoma — The New England Journal of Medicine ESMO 2024 Kidney Cancer Highlights — Kidney Cancer Association Belzutifan Works Steadily in People With VHL-Associated Tumors — National Cancer Institute Center for Cancer Research FDA Approves Bavencio (Avelumab) Plus Inlyta ...
6 Types of Immunotherapy for Kidney Cancer
... — Cancer Research Institute Nivolumab Versus Everolimus in Advanced Renal-Cell Carcinoma — The New England Journal of Medicine ESMO 2024 Kidney Cancer Highlights — Kidney Cancer Association Belzutifan Works Steadily in People With VHL-Associated Tumors — National Cancer Institute Center for Cancer Research FDA Approves Bavencio (Avelumab) Plus Inlyta ...
... Targeted therapy drugs are most often used to treat advanced kidney cancer, but they may be helpful as an adjuvant therapy to lower the risk of recurrence after surgery.Several different targeted therapy drugs can be used to treat kidney cancer, including: Axitinib (Inlyta) Belzutifan (Welireg) Bevacizumab (Avastin) Cabozantinib (Cabometyx) Everolimus ...
8 Kidney Cancer Treatments: Surgery, Immunotherapy, Targeted Therapy, and More
... Targeted therapy drugs are most often used to treat advanced kidney cancer, but they may be helpful as an adjuvant therapy to lower the risk of recurrence after surgery.Several different targeted therapy drugs can be used to treat kidney cancer, including: Axitinib (Inlyta) Belzutifan (Welireg) Bevacizumab (Avastin) Cabozantinib (Cabometyx) Everolimus ...